75%
Involved in 75% of all FDA approvals of oncology compounds since 2012
1M+
1M+ enrolled patients
160K+
Experience working with 160k+ sites worldwide
Dedicated
Full time, on-staff medical and scientific experts dedicated to oncology trials
Your trusted partner in oncology trials
With 50+ years’ experience, Clario’s expertise spans all Phases (I-IV) of oncology trials, and is the partner of choice for top pharmaceutical companies, biotechs and CROs seeking to excel in oncology and solid tumor trials.
Our dedicated team of scientific experts and operational specialists brings unmatched experience and best practices from our long history of successful studies, making us an invaluable collaborator in your trial’s success.
Efficacy: Elevating Disease Progression Assessment
With nearly 2,000 imaging oncology studies, Clario brings proven response criteria expertise complemented by unmatched experience, ensuring you benefit from precision and superior operational processes in your trials.
Key highlights include:
Experience beyond measure
Our extensive involvement in successful solid tumor trials positions us as the unmatched leaders in the field.
Versatile solutions
Our adaptable reader platform and customizable modalities guarantee precise data collection across diverse cancer types and study designs.
Forward-thinking technology
Backed by a robust reader platform and cutting-edge solutions, we redefine the boundaries of clinical research.
Comprehensive imaging platforms
Clario provides software capabilities from automated image de-identification to image analysis platforms that are fully customizable to your study’s endpoints and objectives. Our platforms are centered around robust data capture methods that meet regulatory compliance standards.
Our approach enables you to maximize the potential of your trial’s efficacy assessment, fueling groundbreaking insights and driving the evolution of oncology research.
Learn more about Clario’s efficacy in oncology clinical trials.
Safety: Optimizing for Trial Safety Requirements
Clario’s commitment to patient safety is at the core of our oncology drug development support. With 2,300+ cardiac safety trials and involvement in 70+ novel oncology drug approvals in the past decade, we provide critical insights to sponsors by analyzing patient risk profiles and focusing on safety endpoints.
Our approach includes:
Tailored safety strategies
Our scientific experts collaborate with sponsors to create safety strategies suited to unique program requirements.
Precision analysis
Leveraging technologies like electrocardiogram (ECG), blood pressure, echocardiograms and respiratory assessments, we ensure a thorough understanding of treatment effects. Our centralized ECG solution enhances patient precision and expands patient pools by up to 45%*.
Global reach
We offer robust solutions for trials worldwide, having supported 473,000 oncology patients globally across 54,000 sites and more than 2,400 trials in all phases.
Safety isn’t just a consideration – it’s a cornerstone of our ethos, safeguarding patients and driving the success of your study. As a trusted name in cardiac safety, we use a centralized approach to data collection and offer regulatory consulting on strategic protocol and study design.
*Kleiman et al., 2015
Quality of Life (QoL): Enhancing Patient Well-being
At Clario, we understand that every trial is a journey for patients, and their quality of life is at the heart of our focus.
Our commitment to improving patients’ lives extends to:
Patient-centric approaches
Our electronic Clinical Outcome Assessment (eCOA) solutions empower patients to conveniently share their experiences, enhancing data quality and patient engagement.
Scientific support
In a dynamic regulatory landscape, our scientific expertise and extensive experience stand as differentiators, benefiting clients and trial outcomes alike.
Deeper insights
Through our Cogstate partnership, we use rapid and reliable digital cognitive assessments, along with ePROs, to gauge oncology drugs’ cognitive effects. This insight provides drug developers a competitive advantage, highlighting the therapy’s broader impact beyond tumor response.
Commitment to speed
Clario’s library of pre-built commonly used eCOA oncology assessments gets you from study design to software release in just 5 weeks.
Beyond survival rates, Clario prioritizes the impact of treatments on patients’ mental health and daily functionality, ensuring their well-being remains paramount.
Experience in oncology trials isn’t optional – it’s essential. Trust Clario.
Clario’s expertise in oncology clinical trials encompasses every critical facet – from efficacy and safety to quality of life. Our dedication to excellence is reflected in our comprehensive understanding of:
Protocol design
Crafting a robust study blueprint to ensure effective execution and accurate results.
Endpoint expertise
Clario’s scientists help select the best endpoint solutions for reliable, high-quality data.
Site management
Helping ensure seamless operations at every study location, regardless of scale or complexity.
Patient support
Providing comprehensive assistance to patients, enhancing their experience and ensuring optimal data collection.
Clario’s medical and scientific expertise is revolutionizing what’s possible.
From new trial methodologies to faster and integrated evidence and findings, our innovative oncology trial solutions ensure we deliver the regulatory compliant data you need.
Talk to a specialist
Our team of experts is available to address any questions you may have about our oncology solutions. Submit your contact information and we’ll be in touch shortly.
Oncology Science Team
-
Robert Kleiman, M.D.
Chief Science and Regulatory Advisor, Cardiology
-
Michael O’Neal, M.D.
Chief Medical Officer, Imaging
-
Robert Scarimbolo
VP, Medical & Scientific Affairs, Shared Services
-
Kelly Dumais, Ph.D.
Director, eCOA Science and Consulting
-
Kevin McCarthy, RPFT
Director, Scientific Affairs
-
Adam Jagodinksy, Ph.D.
Scientific Advisor
-
Vrutangkumar Shah, Ph.D.
Director, Data Science and Biostatistics
-
Kathleen Dowell
Vice President, Clinical Adjudication and Specialty Solutions
-
Reina Davis-Aoki, Ph.D.
Clinical Science Associate
-
Vickas Patel, M.D., Ph.D.
Vice President and Chief Medical Officer, Cardiology
-
Betina Bell
Oncology Therapeutic Area Lead
Related resources
Medical imaging data standards, automation and analysis
Innovative approaches to collecting more precise patient experience data for oncology clinical trials
Regulatory guidance for PRO strategy in oncology trials
5 considerations to help differentiate your drug
FAQs
How do you ensure the same level of attention for different sized clients?
Every study, irrespective of its size or complexity, receives the same dedicated attention from Clario, supported by our TA-specific scientists, superior project management and regulatory proficiency—all proven over 50 successful years.
How can Clario ensure quality in the face of cost and time efficiency?
Pride in our 50-year legacy of quality, on-time oncology data delivery fuels our partnership with you. We bring robust scientific acumen, advanced technology across Medical Imaging, Cardiac Safety, eCOA and Precision Motion, and efficient operational execution to deliver the robust, timely data you require.
How are Clario’s solutions compatible with my trial needs?
From planning a clinical trial through endpoint collection to database lock, we partner with our customers every step of the way to generate the rich evidence needed to bring medicines, medical devices and other therapies to market. We do this by being an industry leader across multiple disciplines including:
- Medical Imaging
- Cardiac Safety
- eCOA
- Precision Motion
Can Clario support us not only in the initial stages but also in the long-term?
Absolutely. Think of Clario as your oncology trial’s ally, dynamically scaling and evolving with your trial/team. Our scientific and operational teams’ initial deep dive into your specific needs lays the groundwork for a flexible, adaptable partnership. Not to mention, we have 50+ years’ experience conducting all Phases (I, II, III, IV) of oncology trials; so regardless of the support needed – we will be there.
What if our trial involves novel or complex oncology trial criteria?
Clario’s wide-ranging experience and in-house medical expertise enable us to manage not only standard trials, but also specialize in developing and overseeing novel, complex studies.
Talk to a specialist
Our team of experts is available to address any questions you may have about our oncology solutions. Submit your contact information and we’ll be in touch shortly.